Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation.
Barkhordar M, Kasaeian A, Tavakoli S, Vaezi M, Kamranzadeh Foumani H, Bahri T, Babakhani D, Mirzakhani L, Mousavi A, Mousavi SA, Ghavamzadeh A. Barkhordar M, et al. Int J Hematol Oncol Stem Cell Res. 2021 Jan 1;15(1):51-60. doi: 10.18502/ijhoscr.v15i1.5249. Int J Hematol Oncol Stem Cell Res. 2021. PMID: 33613900 Free PMC article.
Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M, Kasaeian A, Janbabai G, Mousavi SA, Fumani HK, Tavakoli S, Bahri T, Ghavamzadeh A, Vaezi M. Barkhordar M, et al. Leuk Res. 2022 Sep;120:106918. doi: 10.1016/j.leukres.2022.106918. Epub 2022 Jul 12. Leuk Res. 2022. PMID: 35843087
Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia.
Barkhordar M, Kasaeian A, Janbabai G, Kamranzadeh Fumani H, Tavakoli S, Rashidi AA, Mousavi SA, Ghavamzadeh A, Vaezi M. Barkhordar M, et al. Front Immunol. 2022 Aug 5;13:921293. doi: 10.3389/fimmu.2022.921293. eCollection 2022. Front Immunol. 2022. PMID: 35990618 Free PMC article.
Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial.
Barkhordar M, Ahmadvand M, Sharifi Aliabadi L, Noorani SS, Bagheri Amiri F, Janbabai G, Sorouri R, Asadi Milani M, Vaezi M. Barkhordar M, et al. Vaccines (Basel). 2023 Jan 3;11(1):117. doi: 10.3390/vaccines11010117. Vaccines (Basel). 2023. PMID: 36679963 Free PMC article.
Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up.
Tavakoli S, Khalaj F, Kasaeian A, Mousavi SA, Mousavian AH, Arabi F, Rad S, Rostami S, Barkhordar M, Biglari M, Mardani-Fard HA, Alemi H, Khavandgar N, Kamranzadeh Fumani H, Janbabai G, Mousavi SA, Ghavamzadeh A, Vaezi M. Tavakoli S, et al. Among authors: barkhordar m. Cell Transplant. 2023 Jan-Dec;32:9636897231163212. doi: 10.1177/09636897231163212. Cell Transplant. 2023. PMID: 37013251 Free PMC article.
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M, Chahardouli B, Biglari A, Ahmadvand M, Bahri T, Alaeddini F, Sharifi Aliabadi L, Noorani SS, Bagheri Amiri F, Biglari M, Shemshadi MR, Ghavamzadeh A, Vaezi M. Barkhordar M, et al. Front Immunol. 2023 Apr 19;14:1169666. doi: 10.3389/fimmu.2023.1169666. eCollection 2023. Front Immunol. 2023. PMID: 37153556 Free PMC article.
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
Sharifi Aliabadi L, Karami M, Barkhordar M, Hashemi Nazari SS, Kavousi A, Ahmadvand M, Vaezi M. Sharifi Aliabadi L, et al. Among authors: barkhordar m. Front Immunol. 2023 Aug 1;14:1237916. doi: 10.3389/fimmu.2023.1237916. eCollection 2023. Front Immunol. 2023. PMID: 37593732 Free PMC article. Clinical Trial.
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
Sharifi Aliabadi L, Azari M, Taherian MR, Barkhordar M, Abbas SAM, Azari M, Ahmadvand M, Salehi Z, Rouzbahani S, Vaezi M. Sharifi Aliabadi L, et al. Among authors: barkhordar m. Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1. Virol J. 2024. PMID: 38702752 Free PMC article. Review.
25 results